BCL2 and B-cell chronic lymphocytic leukemia: This is perhaps best demonstrated in high-BCL-2-expressing chronic lymphocytic leukemia (CLL) that is often highly sensitive to the BCL-2-selective BH3-mimetic, venetoclax (Roberts et al., 2016).